Demannose

Demannose

SCHEMBL525084

O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TDP1 Q9NUW8 1/20 0.55
PDE4A P27815 1/20 0.46
AKR1B1 P15121 1/20 0.43
USP2 O75604 1/20 0.43
SLCO1B1 Q9Y6L6 1/20 0.43
KDM4E B2RXH2 2/20 0.41
MPI P34949 1/20 0.35
CYP2C19 P33261 1/20 0.33
HIF1A Q16665 1/20 0.33
TOP1 P11387 1/20 0.33
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Demannose SCHEMBL1051912 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL14486320 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL15321015 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL20956808 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL20500378 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL14958551 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL6529193 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL13947310 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Galactose SCHEMBL20818999 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1
Demannose SCHEMBL2290731 1.00 LMNA (0.58) LMNAL3MBTL1TDP1PDE4AAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113663086-B Dendritic cell targeted hybrid dendrimer/YTHDF 1siRNA complex and preparation and application thereof 东华大学 2023-06-23 CN claimed
EP-3362794-B1 METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA EXTHERA MEDICAL CORP (US) 2023-06-07 EP claimed
EP-1639142-B1 A METHOD FOR RECOVERING GALACTOSE FROM A SOLUTION DERIVED FROM PLANT-BASE BIOMASS USING CHROMATOGRAPHIC FRACTIONATION STEPS AND CRYSTALLISATION DUPONT NUTRITION BIOSCI APS (DK) 2015-07-22 EP claimed
EP-1468121-B1 METHOD FOR THE RECOVERY OF SUGARS DANISCO (DK) 2011-11-09 EP claimed
CN-117089479-A Lactic acid bacteria agent suitable for pasture and straw mixed silage and application thereof 贵州省草地技术试验推广站 2023-11-21 CN disclosed
CN-116376767-A Biocontrol strain, microbial inoculum containing biocontrol strain and application of biocontrol strain 沈阳农业大学 2023-07-04 CN disclosed
CN-113663086-B Dendritic cell targeted hybrid dendrimer/YTHDF 1siRNA complex and preparation and application thereof 东华大学 2023-06-23 CN disclosed
CN-115724938-A DM 9-domain-containing recombinant protein rCgDM9CP-7 of crassostrea gigas and application thereof 大连海洋大学 2023-03-03 CN disclosed
CN-115572700-A Pseudomonas mendelia strain with induced disease resistance and application thereof 沈阳农业大学 2023-01-06 CN disclosed
WO-2017185180-A1 THERAPEUTICALLY TRIGGERING AN INNATE IMMUNE RESPONSE IN A TARGET TISSUE QU BIOLOGICS INC. (CA) 2017-11-02 WO disclosed
EP-2760477-A1 DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS Alnylam Pharmaceuticals, Inc. (US) 2014-08-06 EP disclosed
WO-2013049328-A9 DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-12-27 WO disclosed
WO-2009142822-A2 2-F MODIFIED RNA INTERFERENCE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
EP-1625138-A2 PROTECTED MONOMERS Alnylam Pharmaceuticals Inc. (US) 2006-02-15 EP disclosed
EP-1615611-A2 iRNA CONJUGATES Alnylam Pharmaceuticals Inc. (US) 2006-01-18 EP disclosed
WO-2004094345-A2 PROTECTED MONOMERS ALNYLAM PHARMACEUTICALS INC. (US) 2004-11-04 WO disclosed
WO-2004091515-A2 iRNA CONJUGATES ALNYLAM PHARMACEUTICALS, INC. (US) 2004-10-28 WO disclosed
EP-0584206-A1 GENETIC CONTROL OF ACETYLATION AND PYRUVYLATION OF XANTHAN BASED POLYSACCHARIDE POLYMERS GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1994-03-02 EP disclosed
WO-1992019753-A1 GENETIC CONTROL OF ACETYLATION AND PYRUVYLATION OF XANTHAN BASED POLYSACCHARIDE POLYMERS GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1992-11-12 WO disclosed
EP-0115631-A1 Separation of mannose by selective adsorption on zeolitic molecular sieves UNION CARBIDE CORPORATION (US) 1984-08-15 EP disclosed